Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Earnings for Bionomics Limited (BNOX)
Earnings in 2024 (TTM): $-10,271,441
According to Bionomics Limited's latest financial reports the company's current earnings (TTM) are $-10,271,441. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Bionomics Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-10,271,441 | $-15,492,166,000 |
| 2023 | $-32,050,000 | $-31,850,000 |
| 2022 | $-21,950,000 | $-21,760,000 |
| 2021 | $-8,880,000 | $-8,700,000 |
| 2020 | $-6,030,000 | $-7,120,000 |
| 2019 | $-9,910,000 | $-9,670,000 |
| 2018 | $-19,426,170 | $-18,566,770 |
| 2017 | $-4,785,980 | $-5,187,622 |
| 2016 | $-12,905,812 | $-12,360,718 |